$44.42
▲ +1.7% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
Overview
52-week range
$6.34
$26
100% of range
Avg surprise (last 3)
-26.6%
Avg reaction (last 2)
-1.5%
0% positive
Latest IV / EM
123%
EM ±28.1% · $44 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.71 | $-0.47 | -51.1% | -102.9% | -0.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.78 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $-0.50 | $-0.38 | -31.6% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.35 | $-0.36 | +2.8% | — | -2.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.27 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.45 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.76 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | OTHER | -$0.55 | -$0.50 | -10.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-59M | — | $-46M | $-41M | $-32M | — | $-25M | $-24M |
| Net income | $-77M | — | $-67M | $-43M | $-23M | — | $-14M | $-6M |
| EPS (diluted) | $-0.71 | — | $-0.78 | $-0.50 | $-0.35 | — | $-0.27 | $-0.26 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $263M | $258M | $20M | $33M | $83M | $274M | $295M | $243M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $381M | $419M | $216M | $189M | $222M | $282M | $299M | $248M |
| Total assets | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M |
| Long-term debt | $41M | — | $40M | $41M | $22M | — | $24M | $24M |
| Total liabilities | $122M | $108M | $106M | $80M | $53M | $61M | $58M | $66M |
| Total equity | $279M | $332M | $131M | $185M | $223M | $241M | $262M | $202M |